Product Description: Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC)[1][2].
Applications: Cancer-Kinase/protease
Formula: N/A
References: [1]Meina Liang, et al. A Novel Pharmacodynamic Biomarker and Mechanistic Modeling Facilitate the Development of Tovetumab, a Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor Alpha, for Cancer Therapy. AAPS J. 2020 Nov 18;23(1):4. /[2]Naomi Laing, et al. Inhibition of platelet-derived growth factor receptor α by MEDI-575 reduces tumor growth and stromal fibroblast content in a model of non-small cell lung cancer. Mol Pharmacol. 2013 Jun;83(6):1247-56.
CAS Number: 1243266-04-7
Molecular Weight: N/A
Compound Purity: 99.49
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: PDGFR